Press-release for stocks

| 0.25% | O: 0.25% H: 0.0% C: 0.0%
cell meeting therapeutics therapy

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% -21.92% 420K

n/a

| -7.45% | O: -7.45% H: 0.0% C: 0.0%
hepatitis vaccine license granted biopharma virus trial

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
COYA | $7.87 -6.75% -7.24% 54K

| -1.1% | O: -1.1% H: 0.0% C: 0.0%
drug als therapeutics development

Form Bio Establishes Scientific Advisory Board, Comprised of Renowned Experts in Cell and Gene Therapy, for Advancing AI-Driven Therapies
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
FDMT M | $25.29 2.06% 2.02% 630K

| -1.23% | O: -1.23% H: 0.0% C: 0.0%
cell for

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | $1.4 -4.23% 110K

| -23.5% | O: 3.28% H: 2.12% C: -16.4%
topline trial results

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-05 (Crawled : 19:00) - globenewswire.com
CDTX | $0.6855 -5.06% -5.32% 350K

| Email alert Add to watchlist
association cancer research for meeting therapeutics

Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
RVMD S | $34.95 -2.46% -2.52% 1.2M

| 17.3% | O: 0.67% H: 1.8% C: -4.62%
antibody collaboration therapeutics

Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

| -8.12% | O: -1.51% H: 0.0% C: 0.0%
drug collaboration therapeutics

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
FATE | $4.795 -4.86% -5.11% 2.7M

| -20.88% | O: -0.29% H: 7.52% C: 3.39%
conference therapeutics

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.39 -1.42% -1.44% 5.7K

| 2.17% | O: 8.7% H: 3.33% C: -8.67%
ctim-76 application therapeutics

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Published: 2024-03-28 (Crawled : 19:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K

| Email alert Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M

| Email alert Add to watchlist
AVEO | $15.0 0.0% 0

| Email alert Add to watchlist
AUTL | $4.51 -6.04% -6.43% 1.4M

| Email alert Add to watchlist
medical

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
DNLI | $15.98 -3.74% -3.88% 1.5M

| -12.73% | O: 1.33% H: 0.25% C: -1.27%
disease parkinson's health technology biomarkers

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Published: 2024-03-22 (Crawled : 19:00) - globenewswire.com
ESPR | $1.94 3.74% 3.61% 7.3M

Professional, Scientific, and T...

| Email alert Add to watchlist
nexletol fda heart cardiovascular

Gain Therapeutics to Present at Public Ventures Discovery Day
Published: 2024-03-15 (Crawled : 19:00) - globenewswire.com
MDBH | $8.53 1.34% 3.5K

| Email alert Add to watchlist
GANX | $3.155 0.16% 0.16% 71K

| Email alert Add to watchlist
day therapeutics

Biopharma Layoff Tracker 2024: Meissa, Pfizer, Arrakis and More Cut Staff
Published: 2024-03-05 (Crawled : 19:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K

| -13.2% | O: 4.06% H: 5.36% C: -9.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M

| -10.05% | O: -0.3% H: 0.0% C: 0.0%
VXRT | News | $0.7652 -9.15% -10.08% 1.9M

| -28.98% | O: -0.41% H: 1.64% C: -0.82%
TXMD | News | $1.86 -1.59% -1.61% 10K

| -28.27% | O: 0.19% H: 3.03% C: 1.89%
SNY | News | $46.32 2.05% 2.01% 3.3M

| -3.17% | O: 1.17% H: 0.0% C: 0.0%
PTCT | News S | $25.32 2.55% 2.49% 3.9M

| -18.79% | O: -0.87% H: 2.83% C: 1.92%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

| 50.0% | O: -0.93% H: 4.02% C: -0.84%
MOR | News | $17.96 -0.5% -0.5% 180K

| 1.75% | O: -0.28% H: 0.28% C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K

| -15.7% | O: 0.17% H: 0.46% C: -0.6%
AMRN | News | $0.88 0.94% 0.93% 1M

| 0.54% | O: -0.81% H: 9.08% C: 2.68%
GOOGL | News S | $154.08 -1.24% -1.25% 32M

| 16.47% | O: -1.1% H: 1.03% C: 0.6%
GOOG | News S | $155.7 -1.12% -1.13% 20M

| 16.92% | O: -1.09% H: 0.96% C: 0.78%
OCX | News J | $2.495 -2.54% -2.61% 50K

| -13.67% | O: -1.31% H: 3.02% C: 2.0%
biopharma

In Vitro Diagnostic (IVD) Reagents Markets, 2030 - Growing Demand for Protein Therapeutics and Personalized Medicines, Advancements in Diagnostic Technologies Propel Growth
Published: 2024-03-01 (Crawled : 19:00) - prnewswire.com
ABCZF | $22.1 -2.32% 4K

| Email alert Add to watchlist
ABCM | $23.99 0.0% 7.4M

| Email alert Add to watchlist
BDX | $234.12 0.42% 0.0% 1.3M

| Email alert Add to watchlist
QGEN | $40.0 1.34% 0.0% 1.1M

| Email alert Add to watchlist
QGEN | $40.0 1.34% 0.0% 1.1M

| Email alert Add to watchlist
propel diagnostic protein growing therapeutics growth

Biopharma Layoff Tracker 2024: Moderna, Gritstone, Kineta and More Cut Staff
Published: 2024-03-01 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

| -2.32% | O: 0.01% H: 0.0% C: -0.43%
RLYB | News | $1.75 4.79% 4.57% 310K

| -26.45% | O: 1.08% H: 6.81% C: 0.43%
JNJ | News | $147.91 1.49% -0.03% 9.6M

| -10.18% | O: 0.28% H: 0.0% C: 0.0%
VXRT | News | $0.7652 -9.15% -10.08% 1.9M

| -28.69% | O: 2.46% H: 0.8% C: 0.0%
TXMD | News | $1.86 -1.59% -1.61% 10K

| -21.25% | O: 0.0% H: 7.92% C: 5.83%
SNY | News | $46.32 2.05% 2.01% 3.3M

| -5.17% | O: -1.27% H: 0.0% C: 0.0%
PTCT | News S | $25.32 2.55% 2.49% 3.9M

| -10.75% | O: -6.0% H: 24.17% C: 20.57%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

| 90.14% | O: 0.7% H: 11.75% C: 9.09%
MOR | News | $17.96 -0.5% -0.5% 180K

| 2.56% | O: 0.0% H: 0.62% C: 0.57%
GLPG | News | $29.095 0.64% 0.64% 87K

| -16.78% | O: -0.09% H: 0.57% C: 0.09%
AMRN | News | $0.88 0.94% 0.93% 1M

| -13.18% | O: -4.67% H: 3.92% C: 3.92%
GOOGL | News S | $154.08 -1.24% -1.25% 32M

| 12.17% | O: -0.02% H: 0.32% C: -0.93%
GOOG | News S | $155.7 -1.12% -1.13% 20M

| 12.25% | O: -0.12% H: 0.28% C: -1.1%
OCX | News J | $2.495 -2.54% -2.61% 50K

Professional, Scientific, and T...

| -11.0% | O: 2.41% H: 1.51% C: 0.67%
biopharma

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K

| -31.32% | O: 0.22% H: 3.45% C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy

Seeking Alpha Service: Expert Opinions and Smart Investing Converge
Published: 2024-02-13 (Crawled : 19:00) - prnewswire.com
SLVM 4 | $58.46 2.8% 0.0% 380K

Manufacturing

| 25.3% | O: 0.26% H: 0.55% C: -0.31%
ZYME | $8.85 2.08% 2.03% 550K

| -21.54% | O: 1.06% H: 1.23% C: 0.09%
YALA | $4.52 -1.53% -1.55% 390K

| -1.7% | O: 0.42% H: 2.33% C: 1.9%
VST | $65.66 -0.33% 0.0% 7.5M

Utilities

| 55.32% | O: 0.75% H: 1.06% C: -0.58%
TNK | $56.53 1.82% 0.0% 330K

| -1.29% | O: 0.84% H: 0.07% C: -1.45%
SYF | $41.57 1.89% 0.0% 4.5M

| 2.66% | O: 1.27% H: 0.55% C: 0.49%
STNG | $69.53 1.56% 0.0% 720K

| 4.95% | O: 0.04% H: 2.1% C: -1.79%
RGA | $186.52 2.21% 0.0% 520K

| 8.45% | O: 0.26% H: 1.74% C: 1.58%
PGTI | $41.99 -0.0% 2.2M

| 1.65% | O: 0.1% H: 0.12% C: -0.07%
PARR | $31.76 2.22% 0.0% 730K

Energy Minerals

| -18.32% | O: 0.96% H: 0.63% C: 0.2%
PAM | $43.08 2.84% 0.0% 230K

Utilities

| -3.05% | O: 0.3% H: 2.14% C: 1.06%
PAGS | $11.48 -0.61% 0.0% 9M

Commercial Services

| -9.46% | O: 1.63% H: 1.6% C: 1.15%
EPRT A | $25.48 1.27% 2.16% 1.3M

| 2.31% | O: 0.17% H: 0.37% C: -0.21%
ENIC | $2.92 0.31% 170K

Utilities

| 4.44% | O: 1.85% H: 2.55% C: 1.82%
DESP | $11.64 2.83% 0.17% 670K

Consumer Services

| 44.02% | O: 0.99% H: 2.2% C: 1.59%
DHI | $142.19 -2.53% 0.06% 3.4M

Consumer Durables

| 2.58% | O: 1.29% H: 1.46% C: 0.89%
CNC | $75.15 1.9% 0.0% 2.7M

Health Services

| -5.79% | O: 0.26% H: 0.83% C: 0.77%
ASC | $15.88 1.86% 0.0% 470K

| -3.05% | O: 0.67% H: 0.41% C: -1.57%
STNE | $15.3 0.26% 0.26% 7.2M

| -10.34% | O: 1.65% H: 1.85% C: 1.27%
SPOK | $15.0 0.74% 0.73% 98K

Communications

| -7.22% | O: 0.93% H: 0.49% C: -0.06%
RCMT | $19.14 0.21% 0.16% 52K

Industrial Services

| -34.21% | O: 0.7% H: 1.71% C: 0.63%
PGTI | $41.99 -0.0% 2.2M

| 1.65% | O: 0.1% H: 0.12% C: -0.07%
MGNX | $15.62 -2.8% -2.88% 1M

| -7.2% | O: -4.21% H: 6.5% C: 3.07%
LMB 4 | $39.35 -1.67% -1.7% 300K

Miscellaneous

| -6.76% | O: 1.85% H: 4.24% C: 4.24%
LI | $26.365 -9.65% -10.68% 12M

| 0.33% | O: 2.58% H: 0.2% C: -1.53%
ITRN | $24.99 -0.12% -0.12% 21K

Electronic Technology

| -0.2% | O: 1.74% H: 2.41% C: 2.33%
FCNCA | $1568.1 1.04% 1.03% 65K

| 3.55% | O: 0.87% H: 1.12% C: 0.01%
FITB | $36.225 5.86% 5.53% 14M

| 3.9% | O: 1.28% H: 1.04% C: 0.81%
ESEA | $33.45 1.98% 1.94% 20K

| -6.28% | O: 1.12% H: 1.28% C: -3.77%
CCAP | $17.165 0.5% 0.5% 78K

| 5.97% | O: 0.37% H: 0.06% C: -0.12%
BWAY | $4.835 0.94% 0.93% 41K

| -25.39% | O: 2.18% H: 6.4% C: -0.3%
BELFB | $56.62 1.05% 1.04% 73K

Electronic Technology

| -15.27% | O: 1.22% H: 5.5% C: 4.52%
BELFA | $69.18 -0.04% -0.04% 7.3K

Electronic Technology

| -5.77% | O: 1.03% H: 4.49% C: 4.04%
ARCT 4 | $25.995 -1.23% -1.25% 630K

| -32.11% | O: 2.14% H: 0.58% C: -2.88%
ALKS | $23.86 0.42% 0.42% 2.4M

| -12.74% | O: 0.99% H: 1.93% C: 1.78%
SILV | $7.9 4.36% 0.0% 2.1M

Non-Energy Minerals

| 40.28% | O: 0.59% H: 1.56% C: 0.2%
smart

Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
Published: 2024-02-12 (Crawled : 19:00) - prnewswire.com
WISH | News | $5.84 1.74% 1.71% 1.5M

| -20.77% | O: -1.76% H: 3.9% C: 1.95%
DOOR | $131.39 0.07% 660K

| 0.52% | O: 0.01% H: 0.22% C: -0.19%
JNJ | News | $147.91 1.49% -0.03% 9.6M

| -7.44% | O: 0.7% H: 0.0% C: 0.0%
CBAY | $32.48 0.03% 8.4M